Similarity-based classifier using topomers to provide a knowledge base for hERG channel inhibition

Journal of Chemical Information and Modeling

Volumn 49, Issue 2, 2009, Pages 247-256

  Nisius, Britta ^a   Göller, Andreas H ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FORECASTING; KNOWLEDGE BASED SYSTEMS; QUERY PROCESSING;

ADMET PROPERTIES; CARDIAC ARRHYTHMIA; CHANNEL ACTIVITY; DRUG DISCOVERY PROCESS; EARLY PREDICTION; PROOF OF PRINCIPLES; SEARCH TECHNOLOGY; SIMILARITY MEASURE;

MOLECULES;

ERG1 POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG;

ANIMAL; ARTICLE; CELL LINE; DRUG ANTAGONISM; HUMAN; KNOWLEDGE BASE;

ANIMALS; CELL LINE; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; KNOWLEDGE BASES;

EID: 65249092596     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci800304t     Document Type: Article

References (50)

1. Warmke, J. W.; Ganetzky, B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3438-3442.
2. Mitcheson, J. S.; Perry, M. D. Molecular determinants of high-affinity drug binding to hERG channels. Curr. Opin. Drug. Discovery Dev. 2003, 6, 667-674.
3. Sanguinetti, M. C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440, 463-469.
4. Antzelevitch, C.; Shimizu, W. Cellular mechanisms underlying the long QT syndrome. Curr. Opin. Cardiol. 2002, 17, 43-51.
5. Aronov, A. M. Predictive in silico modeling for hERG channel blockers. Drug Discovery Today 2005, 10, 149-155.
6. De Pond, F.; Poluzzi, E.; Montanaro, N. QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience. Eur. J. Clin. Pharmacol. 2000, 56, 1-18.
7. + channel blockade: Current knowledge and strategies for the early prediction during drug development. Med. Res. Rev. 2005, 25, 133-166.
8. Wood, C.; Williams, C.; Waldron, G. J. Patch clamping by numbers. Drug Discovery Today 2004, 9, 434-441.
9. Brown, A. Drugs, hERG and sudden death. Cell Calcium 2004, 35, 534-546.
10. Dubin, A. E.; Nasser, N.; Rohrbacher, J.; Hermans, A. N.; Marrannes, R.; Grantham, C.; Van Rossem, K.; Cik, M.; Chaplan, S. R.; Gallacher, D.; Xu, J.; Guia, A.; Byrne, N. G.; Mathes, C. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J. Biomol. Screen. 2005, 10, 168-181.
11. Bridgland-Taylor, M. H.; Hargreaves, A. C.; Easter, A.; Orme, A.; Henthorn, D. C.; Ding, M.; Davis, A. M.; Small, B. G.; Heapy, C. G.; Abi-Gerges, N.; Persson, F.; Jacobson, I.; Sullivan, M.; Albertson, N.; Hammond, T. G.; Sullivan, E.; Valentin, J.-P.; Pollard, C. E. Optimization and validation of a medium-throughput electrophysiology-based hERG assay using Ion Works HT. J. Pharmacol. Toxicol. Methods 2006, 54, 189-199.
12. Thai, K.-T.; Ecker, G. F. Predictive models for hERG channel blockers: Ligand-based and structure-based approaches. Curr. Med. Chem. 2007, 14, 3003-3026.
13. + channel blockers. J. Med. Chem. 2002, 45, 3844-3853.
14. Ekins, S.; Crumb, W. J.; Sarazan, R. D.; Wikel, J. H.; Wrighton, S. A. Three-dimensional quantitative structure-activity relationships for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 2002, 301, 427-434.
15. Pearlstein, R. A.; Vaz, R. J.; Kang, J.; Chen, X.-L.; Preobrazhenskaya, M.; Shchekotikhin, A. E.; Korolev, A.; Lysenkova, L. N.; Miroshnikova, O. V.; Hendrix, J.; Rampe, D. Characterization of hERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. 2003, 13, 1829-1835.
16. Li, Q.; Jorgensen, F. S.; Oprea, T.; Brunak, S.; Taboureau, O. hERG classification model based on a combination of support vector machine method and GRIND descriptors. Mol. Pharm. 2007, 5, 117-127.
17. Yap, C. W.; Cai, C. Z.; Xue, Y.; Chen, Y. Z. Prediction of torsadecausing potential of drugs by support vector machine approach. Toxicol. Sci. 2004, 79, 170-177.
18. Seierstad, M.; Agrafiotis, D. K. A QSAR model of hERG binding using a large, diverse, and internally consistent training set. Chem. Biol. Drug. Des. 2006, 67, 284-296.
19. Roche, O.; Trube, G.; Zuegge, J.; Pfimlin, P.; Alanine, A.; Schneider, G. A virtual screening method for prediction of the hERG potassium channel liability of compound libraries. ChemBioChem 2002, 3, 455-459.
20. Gepp, M. M.; Flutter, M. C. Determination of hERG channel blockers using a decision tree. Bioorg. Med. Chem. 2006, 14, 5325-5332.
21. Dubus, E.; Ijjaali, I.; Petitet, F.; Michel, A. In silico classification of hERG channel blockers: A knowledge-based strategy. ChemMedChem 2006, 1, 622-630.
22. Sun, H. An accurate and interpretable Bayesian classification model for prediction of hERG liability. ChemMedChem 2006, 1, 315-322.
23. Obrezanova, O.; Csanyi, G.; Gola, J. M. R.; Segall, M. D. Gaussian process: A method for automatic QSAR modeling of ADME properties. J. Chem. Inf. Model. 2007, 47, 1847-1857.
24. Thai, K.-M.; Ecker, G. F. A binary QSAR model for classification of hERG potassium channel blockers. Biorg. Med. Chem. 2008, 16, 4107-4119.
25. Kramer, C.; Beck, B.; Kriegl, J. M.; Clark, T. A composite model for hERG blockade. ChemMedChem 2007, 3, 254-165.
26. Concepts and applications of molecular similarity; Johnson, M., Maggiora, G. M., Eds.; John Wiley and Sons: New York, 1990.
27. Maggiora, G. M. On outliers and activity cliffs - Why QSAR often disappoints. J. Chem. Inf. Model. 2006, 46, 1535-1535.
28. Peltason, L.; Bajorath, J. SAR Index: Quantifying the nature of structure-activity relationships. J. Med. Chem. 2007, 50, 5571-5578.
29. Guha, R.; Van Drie, J. H. Structure-Activity Landscape Index: Identifying and quantifying activity cliffs. J. Chem. Inf. Model. 2008, 48, 646-658.
30. Guha, R.; Van Drie, J. H. Assessing how well a modeling protocol captures a structure-activity landscape. J. Chem. Inf. Model. 2008, 48, 1716-1728.
31. Wawer, M.; Peltason, L.; Weskamp, N.; Teckentrup, A.; Bajorath, J. Structure-activity relationship anatomy by network-like similarity graphs and local structure-activity relationship indices. J. Med. Chem. 2008, 51, 6075-6084.
32. Martin, Y. C.; Kofron, J. L.; Traphagen, L. M. Do structurally similar molecules have similar biological activity. J. Med. Chem. 2002, 45, 4350-4358.
33. Kubinyi, H. Chemical similarity and biological activities. http:// www.kubinyi.de/Ald-06.pdf (accessed October 15, 2008).
34. Cramer, R. D.; Jilek, R. J.; Andrews, K. M. Dbtop: Topomer similarity searching of conventional databases. J. Mol. Graphics Modell. 2002, 20, 447-462.
35. + channels expressed in mammalian cell lines and Xenopus oocytes. J. Pharmacol. Toxicol. Methods 2002, 48, 65-80.
36. Jilek, R. J.; Cramer, R. D. Topomers: A validated protocol for their self-consistent generation. J. Chem. Inf. Comput. Sci. 2004, 44, 1221-1227.
37. Sivanandam, S. N.; Deepa, S. N. Introduction to Genetic Algorithms; Springer: Berlin, Heidelberg, 2007.
38. Devillers, J. Genetic Algorithms in Molecular Modeling; Academic Press: New York, 1996.
39. Matthews, B. W. Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim. Biophys. Acta 1975, 405, 442-451.
40. Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63144-2319, U.S.A. Dbtop documentation as provided for Beta-testing in 2006.
41. Pipeline Pilot, version 6.1.5; Accelrys Inc.: 10188 Telesis Court, Suite 100, San Diego, CA 92121, U.S.A.
42. Buyck, C.; Tollenaere, J.; Engels, M.; Clerck, F. D. An in silico model for detecting potential hERG blocking. Poster presentation. Euro-QSAR 2002, Bournemouth, Sep 8-13, 2002.
43. + channel blockers. Bioorg. Med. Chem. 2004, 12, 307-2315.
44. Duffy, E. M.; Jorgensen, W. L. Prediction of properties from simulations: Free energies of solvation in hexadecane, octanol, and water. J. Am. Chem. Soc. 2000, 122, 2878-2888.
45. McGregor, G. B.; Pallai, P. Clustering of large databases of compounds: Using the MDL "keys" as structural descriptors. J. Chem. Inf. Comput. Sci. 1997, 37, 443-448.
46. Durant, J.; Leland, B.; Henry, D.; Nourse, J. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf. Comput. Sci. 2002, 42, 1273-1280.
47. Rogers, D.; Brown, R. D.; Hahn, M. Using extended- connectivityfingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up. J. Biomol. Screening 2005, 10, 682-686.
48. Gavaghan, C. L.; Hasselgren Arnby, C.; Blomberg, N.; Strandlund, G.; Boyer, S. Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data. J. Comput.-Aided Mol. Des. 2007, 21, 189-206.
49. O' Brien, S. E.; de Groot, M. J. Greater than the sum of its parts: Combining models for useful ADMET prediction. J. Med. Chem. 2005, 48, 1287-1291.
50. Tong, W.; Hong, H.; Xie, Q.; Shi, L.; Fang, H.; Perkins, R. Assessing QSAR Limitations - A Regulatory Perspective. Curr. Comput.-Aided Drug Des. 2005, 11, 195-205.